Skip to content

Life Sciences

CPV: one abbreviation, two different things

  • Life Sciences
  • 1 min read

Continued, ongoing and continuous process verification are three phrases for two different things.

Continued process verification is the FDA's name for Stage 3 of process validation. The 2011 guidance defines it as assuring that during routine production the process remains in a state of control.

EU GMP Annex 15 (2015) describes the same activity and calls it ongoing process verification. Its glossary adds "also known as continued process verification", so those two are one.

Continuous process verification is the other thing. ICH Q8(R2) defines it as an alternative approach to process validation in which manufacturing process performance is continuously monitored and evaluated. Annex 15 (2015) says it can be used as an alternative to traditional process validation for products developed by a quality by design approach, where development has scientifically established that the control strategy gives a high degree of assurance of product quality. A site that makes three validation batches and then trends its data is doing the first thing, not this one.

Two of the three shorten to CPV, which is where reports go wrong. "CPV was applied" means a monitoring program to one reader and an alternative way of validating to another.

In a protocol or a report, write the phrase out once and cite the document it comes from.

Industries

Related

More on this subject

Taking over a facility: start with a written gap assessment

Before changing an inherited facility or design, a written gap assessment against the URS and target regulations gives management and inspectors the same picture: evidence from documents and spot measurements, findings graded by risk, and the fix, cost range and schedule impact of each, plus what can stay.

InsightRead

The receiving site validates the process again

A process validated at the sending site was validated with that site's equipment, utilities and people. WHO's technology transfer guideline defines validation batches as those produced by the receiving unit, and EU GMP Annex 15 (2015) covers site transfers. The earlier validation supports the new protocol. With bracketing, the number of batches could be reduced; the content of the previous validation should be available.

InsightRead

EU GMP Annex 15 (2015) treats three consecutive PPQ batches as a common minimum, with the number justified from risk; the FDA's 2011 guidance names no count and works in three stages. A rationale that serves both draws on commercial-scale variability, parameters near their proven limits, prior knowledge and a statistical target on the CQAs.

InsightRead